TY - JOUR
T1 - Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome
AU - Coppola, G.
AU - Grosso, S.
AU - Franzoni, E.
AU - Veggiotti, P.
AU - Zamponi, N.
AU - Parisi, P.
AU - Spalice, A.
AU - Habetswallner, F.
AU - Fels, A.
AU - Verrotti, A.
AU - D'Aniello, A.
AU - Mangano, S.
AU - Balestri, A.
AU - Curatolo, P.
AU - Pascotto, A.
PY - 2011/2
Y1 - 2011/2
N2 - Background: To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7± 8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3-26 months).Results: Fifteen of 38 patients (39.5%) had a >50% seizure reduction in countable seizures. Complete seizure freedom was achieved in one of these patients (2.6%). Three patients (7.9%) had a 25-49% seizure reduction, whilst seizure frequency remained unchanged in 15 (39.5%) and increased in five patients (13.1%). Eleven patients (28.9%) reported adverse side effects. Vomiting was reported in five patients (13.1%); drowsiness, decreased appetite and irritability with migraine manifested in other four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug for the treatment of refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Rufinamide was most effective in patients with drop-attacks and (bi)frontal spike-wave discharges.
AB - Background: To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7± 8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3-26 months).Results: Fifteen of 38 patients (39.5%) had a >50% seizure reduction in countable seizures. Complete seizure freedom was achieved in one of these patients (2.6%). Three patients (7.9%) had a 25-49% seizure reduction, whilst seizure frequency remained unchanged in 15 (39.5%) and increased in five patients (13.1%). Eleven patients (28.9%) reported adverse side effects. Vomiting was reported in five patients (13.1%); drowsiness, decreased appetite and irritability with migraine manifested in other four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug for the treatment of refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Rufinamide was most effective in patients with drop-attacks and (bi)frontal spike-wave discharges.
KW - Epileptic encephalopathies-childhood
KW - Refractory seizures
KW - Rufinamide
UR - http://www.scopus.com/inward/record.url?scp=78751503816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751503816&partnerID=8YFLogxK
U2 - 10.1111/j.1468-1331.2010.03113.x
DO - 10.1111/j.1468-1331.2010.03113.x
M3 - Article
C2 - 20666837
AN - SCOPUS:78751503816
VL - 18
SP - 246
EP - 251
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
IS - 2
ER -